THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
8
https://www.theamericanjournals.com/index.php/tajmspr
PUBLISHED DATE: - 14-06-2024
https://doi.org/10.37547/TAJMSPR/Volume06Issue06-02
PAGE NO.: - 08-17
THE CONTRIBUTION OF NON-ALCOHOLIC
FATTY LIVER DISEASE TO THE
PROGRESSION OF ATHEROSCLEROSIS
S.I. Sadikova
Associate Professor, Department Of Internal Medicine, Family Medicine No.
2, Tashkent Medical Academy, Tashkent, Uzbekistan
N. S.- Khodjaeva
Doctor Of The Highest Category Of Ultrasound Diagnostics At The Akfa
University Clinicmedline, Tashkent, Uzbekistan
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is now
identified as a leading chronic liver condition
worldwide[1]. Despite the challenge in pinpointing
precise incidence rates, estimates suggest that
NAFLD affects 20
–
30% of populations in Western
countries and 5
–
18% in Asian countries, with these
numbers increasing sharply over time. It's believed
that NAFLD impacts about 25
–
30% of people
globally[2].
This
condition,
along
with
cardiovascular
diseases
and
metabolic
disturbances in lipid and carbohydrate metabolism
associated with insulin resistance (IR) syndrome, is
gaining increased attention. NAFLD covers a broad
range of metabolic liver damages in the context of
IR, including simple fatty liver (steatosis), steatosis
with inflammation and liver cell damage (non-
alcoholic steatohepatitis, NASH), and fibrosis,
which can evolve into cirrhosis of the liver[3, 4].
The outlook for individuals diagnosed with NAFLD
is concerning; about 40% of those with simple
steatosis progress to NASH within 8-13 years, and
from this group, 15% may develop liver cirrhosis
and liver failure. Moreover, 7% of patients with
liver cirrhosis are at risk of developing
hepatocellular carcinoma (HCC) within a
decade[5]. The expectation is that NAFLD will soon
become the predominant liver disorder, already
RESEARCH ARTICLE
Open Access
Abstract
THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
9
https://www.theamericanjournals.com/index.php/tajmspr
being the second leading cause of HCC and liver
transplants[6].
Research has highlighted a significant link between
the onset of non-alcoholic fatty liver disease
(NAFLD) and several metabolic conditions, such as
obesity, type 2 diabetes mellitus (T2DM), and
atherogenic dyslipidemia, particularly in cases
where insulin resistance (IR) is present. Within the
general European population, the occurrence rate
of NAFLD is found to be between 20-33%. This rate
escalates among individuals diagnosed with type 2
diabetes mellitus, where it is observed to vary from
42.6-69%. This data underscores the intertwined
nature of metabolic diseases and the critical role of
insulin resistance in the development of NAFLD[7,
8].
Furthermore, there's an ongoing dialogue around
genetic mutations affecting carbohydrate and lipid
metabolism, which result in changes to insulin
sensitivity within the liver[9; 10]. These genetic
factors contribute to the broader understanding of
NAFLD's pathogenesis and its strong links to other
symptoms of insulin resistance (IR). This
connection positions non-alcoholic fatty liver
disease (NAFLD) as a liver-centered component of
metabolic syndrome[11; 12]. Yet, as the liver
engages in this pathological sequence, it transitions
from being merely an affected organ to an active
participant that intensifies the metabolic
imbalances associated with IR.
Studies have shown that disruptions in insulin
breakdown and glucose usage occur in the liver
during fatty hepatosis, leading to an environment
conducive to the production of atherogenic
cholesterol fractions and triglycerides (TG). These
disruptions
are
instrumental
in
causing
disturbances
in
carbohydrate
and
lipid
metabolism, precipitating the early emergence of
atherosclerosis and subsequent cardiovascular
diseases[13; 14]. Research by Natadisa M. in 2007
further illuminates the heightened risk of
atherosclerosis in individuals with NAFLD, which is
found to be 4.12 times greater than in those
without the disease, as indicated by a 95%
confidence interval (CI) of 1.58-10.75 and a
significance level of p=0.004. Additionally, the
study highlights a gender disparity in the risk of
cardiovascular complications associated with
NAFLD, with women facing a risk 7.32 times higher
compared to men's 3.56 times, showcasing a
significant difference (p<0.027)[15].
Atherosclerosis is identified as a condition that
involves the liver, where it's established that two
main factors are essential for its onset: lipid
metabolism disorders and vascular endothelium
damage. Within the scope of NAFLD, the
disturbance in lipid metabolism is evidenced by
increased low-density lipoprotein cholesterol
(LDL-C) levels, decreased high-density lipoprotein
cholesterol (HDL-C) levels, and the presence of
hypertriglyceridemia. The harm to arterial
endothelium associated with liver diseases stems
from various factors, including oxidized LDL lipids,
elevated C-reactive protein (CRP) levels,
heightened activity of lipoprotein-associated
phospholipase
A2,
hyperglycemia,
insulin
resistance, raised homocysteine levels, increased
fibrinogen levels, and a scarcity of nitric oxide
(NO). These elements collectively contribute to the
complex interplay between NAFLD and the
development of atherosclerosis [16].
Enhanced arterial stiffness in individuals with non-
alcoholic fatty liver disease (NAFLD) is garnering
notable focus, positioning NAFLD as a marker for
this condition[24]. This increased stiffness of
arteries, which persists even when traditional
cardiovascular risk factors are accounted for, is
linked with NAFLD. Patients with NAFLD show
reduced elasticity and flexibility of the aorta,
indicating that both the presence and severity of
NAFLD correlate with heightened arterial stiffness,
regardless of the existence of hypertension (HTN)
or diabetes mellitus (DM) [17].
In the "Cardio-GOOSE" study, the assessment of
arterial stiffness was conducted through the
measurement of carotid-femoral pulse wave
velocity (PWV) and detection of subclinical
atherosclerosis via intima-media thickness (IMT).
Results showed no significant difference in IMT
between those with and without NAFLD
(0.77±0.15
mm
versus
0.76±0.14
mm,
respectively) [18]. However, for individuals
THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
10
https://www.theamericanjournals.com/index.php/tajmspr
diagnosed with both NAFLD and metabolic
syndrome (MS), IMT values were noticeably higher
(0.85±0.16 mm; p<0.005) compared to those
without MS. Furthermore, an increase in vascular
wall stiffness was observed in patients with
NAFLD, especially pronounced in those also
suffering from MS, with the PWV measurements
being higher in the NAFLD+MS group (8.29±2.2
m/s; p<0.001). The occurrence of NAFLD was more
common in participants exhibiting greater vascular
stiffness, even after adjusting for MS (p<0.05),
highlighting the intricate relationship between
NAFLD and cardiovascular health [19].
Non-alcoholic fatty liver disease (NAFLD) is linked
to a heightened risk of atherosclerosis, including its
asymptomatic stages, highlighted by increased
intima-media thickness (IMT) and raised levels of
C-reactive protein (CRP). According to research
conducted by Kim in 2009, the IMT in patients with
NAFLD was found to be 0.034 mm thicker than in
those without the condition, a difference that was
statistically
significant
(p=0.016)
[20].
Additionally, individuals with NAFLD are more
likely to have silent atherosclerotic changes in the
carotid arteries. The occurrence of atherosclerotic
plaques is notably higher among patients with
NAFLD, with a prevalence of 57.8%, compared to
37.5% in those without NAFLD (p=0.02).
Furthermore, the likelihood of developing carotid
atherosclerosis in patients with NAFLD is
increased by 1.85 times (p<0.001), underscoring
the significant impact of NAFLD on cardiovascular
health and the importance of monitoring for
atherosclerotic changes in this patient population
[21].
Over a span of 21 years, cardiovascular diseases
have been identified as the leading cause of
mortality among individuals diagnosed with non-
alcoholic fatty liver disease (NAFLD). Additionally,
NAFLD is linked to a rise in not just cardiovascular-
related deaths but also overall mortality rates. This
interplay of factors considerably hastens the onset
and advancement of atherosclerosis and its related
cardiovascular conditions. As a result, investigating
NAFLD as a separate and contributory risk factor in
the progression of atherosclerosis has become a
focal point of contemporary research, highlighting
the importance of recognizing and managing
NAFLD to potentially mitigate the risk of
cardiovascular complications [22].
Purpose.Our research aimed to evaluate the
predictive value of non-alcoholic fatty liver disease
(NAFLD) in identifying the likelihood of early signs
of atherosclerotic vascular damage, with a specific
focus on the lower extremities. This study sought
to understand how NAFLD could serve as an
indicator for the onset of atherosclerosis in these
areas, potentially offering insights into the broader
implications of NAFLD on cardiovascular health
and the importance of early detection and
management of vascular risks associated with this
liver condition.
MATERIAL AND METHODS OF RESEARCH
Our investigation encompassed 100 individuals,
aged 35 to 45 years, who were participating in
standard health screenings at the "Akfa Medline"
university clinic in Tashkent. These participants
were asymptomatic at the time of their evaluation.
The study set specific exclusion criteria to ensure a
homogeneous sample population, disqualifying
individuals with obesity (defined by a div mass
index not exceeding 30 kg/m^2), hypertension,
coronary artery disease, type 2 diabetes mellitus,
and renal or gastrointestinal diseases that
necessitated drug treatment. This approach aimed
to isolate the impact of non-alcoholic fatty liver
disease (NAFLD) on the early development of
atherosclerotic vascular changes in the lower
extremities, minimizing confounding factors that
could influence the outcomes.
In gathering data on alcohol consumption history,
our methodology adhered to the guidelines set
forth by the World Health Organization (WHO)
from the year 2000. We specifically focused on
alcohol intake levels and only considered
consumption patterns that exceeded WHO's
recommended norms if they occurred within the
last five years; any excessive alcohol consumption
more than 5 years prior was not included in our
analysis. Additionally, we meticulously excluded
any participants with a history of viral hepatitis or
THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
11
https://www.theamericanjournals.com/index.php/tajmspr
liver
damage
attributed
to
toxins
or
pharmaceuticals. This careful selection process
aimed to ensure the accuracy of our study by
eliminating potential confounding factors related
to liver health and focusing on the impact of non-
alcoholic factors on liver disease.
A comprehensive physical examination of the
participants was carried out, which included the
measurement of key anthropometric indicators
and blood pressure levels to assess overall health
status. In addition, a detailed analysis of lipid
profile markers was performed. This analysis
involved determining the levels of total cholesterol
(TC), high-density lipoprotein cholesterol (HDL-C),
triglycerides (TG), and low-density lipoprotein
cholesterol (LDL-C). These measurements were
crucial for evaluating the metabolic and
cardiovascular health of the participants, providing
essential insights into their risk factors for
developing conditions such as atherosclerosis and
cardiovascular diseases, particularly in the context
of non-alcoholic fatty liver disease (NAFLD).
The evaluation of the intima-media thickness (IMT)
of the common carotid arteries (CCA) was executed
employing a standardized approach on the
ACUSON S2000 and S3000 2019 ultrasound
machines, which were outfitted with a linear probe
that utilizes a phased array technology at a
frequency of 7.5 MHz. This examination targeted
the CCA at three distinct locations, specifically 2 cm
below the bifurcation point on both the right and
left sides of the neck. To derive the average IMT
value for the CCA, measurements from these six
points were aggregated. The criteria for identifying
early indications of atherosclerosis involved
detecting a localized increase in the CCA IMT to
more than 1.5 mm at any measured site along the
carotid artery, denoted as the maximum CCA IMT.
This measurement process is critical for diagnosing
the preliminary stages of atherosclerosis, offering
valuable insights into the cardiovascular risk
profile of the study participants.
All participants in the study were subjected to a
liver ultrasound examination to assess various
aspects of liver health, including the oblique
vertical size of the liver (OVS), the density of the
liver parenchyma, the condition of the liver bile
ducts, and the vascular pattern. For capturing
detailed images of the liver parenchyma,
performing measurements of its lobes, and
evaluating its structure, the Acuson Sequoia Expert
system 2022 was employed. This advanced
ultrasound system is equipped with a convex probe
that features a phased array with a frequency of 3.5
MHz, making it particularly suited for B-mode
scanning of internal organs.
The liver ultrasound procedure was carried out in
accordance with the standard methodological
guidelines as outlined by V. V. Mitkov in 2007. This
ensured that the examination was performed
consistently and accurately across all patients,
allowing for the reliable assessment of liver health
and the identification of potential indicators of
non-alcoholic fatty liver disease (NAFLD) or other
liver-related conditions.
The evaluation of the liver's architecture and
vascular pattern was conducted meticulously. The
diagnosis of fatty infiltration within the liver was
determined through a comprehensive assessment,
which included examining the oblique vertical size
(OVS) of the liver, its echogenicity, the vascular
pattern, and the sound conduction properties of
the liver parenchyma. These criteria are crucial for
identifying the presence and extent of fatty
infiltration, as changes in echogenicity and sound
conduction often indicate increased fat deposits
within the liver tissue. Moreover, alterations in the
vascular pattern can suggest changes in liver
density and structure associated with fatty liver
disease. This approach allows for a detailed
understanding of liver health and the identification
of non-alcoholic fatty liver disease (NAFLD) or
other conditions that might impact the liver's
function and structure.
The analysis of statistical data was carried out
using the SPSS software, version 11.0, a standard
package for statistical analysis. Quantitative data
were summarized using the mean value and the
standard error of the mean (M ± m), providing a
clear depiction of the central tendency and
variability within the data. To determine the
significance of the differences observed between
THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
12
https://www.theamericanjournals.com/index.php/tajmspr
various groups in the study, the Student's t-test
was employed, a widely used method for
comparing means.
Furthermore, to ascertain the prognostic relevance
of the characteristics under study, a multivariate
stepwise regression analysis was performed. This
advanced statistical method allows for the
identification of the most significant predictors
among a set of variables, thereby understanding
their combined effect on a particular outcome. The
threshold for statistical significance was set at a
probability level of p < 0.05, meaning that results
with a p-value less than 0.05 were considered
statistically significant. This rigorous analytical
approach ensured that the findings of the study
were both reliable and valid, contributing valuable
insights into the prognostic significance of various
factors in relation to the health conditions being
investigated.
RESEARCH RESULTS
In our study, fatty infiltration of the liver
parenchyma was identified in 48 participants, who
were then categorized into the primary study
group. This group exhibited increased echogenicity
within the altered liver parenchyma, which was
indicative of fatty infiltration. Additionally, an
acoustic phenomenon of ultrasound attenuation
was noted in the deeper layers of the parenchyma,
suggesting alterations in the liver's structure due to
fat accumulation. Despite these changes, the liver
parenchyma's structure appeared homogeneous,
and there were no alterations in the organ's shape;
the liver maintained smooth contours and a sharp
edge, indicating no significant morphological
distortion.
The oblique vertical size (OVS) of the right liver
lobe emerged as a particularly informative and
widely accepted measure for assessing liver health.
Within the NAFLD group, the OVS of the right liver
lobe in 12 patients (accounting for 27.3% of the
group) exceeded the established threshold values,
measuring more than 140 mm, signaling significant
liver enlargement.
For comparison, a control group was established,
comprising 52 individuals who showed no
ultrasound evidence of NAFLD. This distinction
between the groups based on ultrasound findings
of the liver allowed for a comparative analysis,
further highlighting the impact of fatty infiltration
on liver structure and function.
The study ensured that the groups were well-
matched in terms of gender, age, Body Mass Index
(BMI), and alcohol consumption history,
facilitating a reliable comparison. Specifically,
within both the primary and control groups, a
similar percentage of patients reported low-dose
alcohol consumption, with 54.6% in the main
group and 58.9% in the control group. The average
age of participants was 41.1 ± 2.1 years in the main
group and 37.2 ± 1.9 years in the control group,
showing no statistically significant difference
between the two (p = 0.172).
Among the patients with non-alcoholic fatty liver
disease (NAFLD), the fasting blood glucose level
was notably higher at 5.35 ± 0.07 mmol/L, in
contrast to the control group's average of 5.05 ±
0.07 mmol/L (p = 0.006), indicating a significant
shift in carbohydrate metabolism. Indeed, fasting
hyperglycemia was present in 45.5% of the NAFLD
group compared to 26.8% in the control group (p =
0.010), highlighting a marked difference in glucose
regulation.
Furthermore, alterations in lipid profile indicators
were significantly more prevalent among patients
with NAFLD. The average total cholesterol (TC)
level in the NAFLD group was notably higher than
the norm and exceeded that of the control group, at
5.96 ± 0.21 mmol/L versus 5.11 ± 0.15 mmol/L,
respectively (p = 0.001). Triglyceride (TG) levels
were also substantially elevated in the NAFLD
group, at 1.72 ± 0.20 mmol/L, compared to 0.81 ±
0.05 mmol/L in the control group (p < 0.001).
Additionally, low-density lipoprotein cholesterol
(LDL-C) levels were higher in the main group, at
3.89 ± 0.20 mmol/L, versus 3.24 ± 0.12 mmol/L in
the control group (p = 0.004), underscoring
significant differences in lipid metabolism between
those with and without NAFLD.
In both groups, levels of high-density lipoprotein
cholesterol (HDL-C) were found to be within
THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
13
https://www.theamericanjournals.com/index.php/tajmspr
normal ranges. However, in the group with non-
alcoholic fatty liver disease (NAFLD), a significant
40.9% of patients showed lipid profile changes that
exceeded the threshold for atherogenic cholesterol
fractions, a stark contrast to only 1.8% in the
control group (p < 0.001). This indicates a
markedly higher prevalence of atherogenic lipid
profiles among individuals with NAFLD.
The functional state of the liver, as indicated by
enzyme activity levels, revealed significant
differences between the groups. In the NAFLD
group, both alanine aminotransferase (ALT) and
gamma-glutamyl transferase (GGT) levels were
notably higher, with ALT levels at 43.2 ± 3.22 U/L
and GGT levels at 51.9 ± 11.6 U/L, compared to 24.4
± 1.82 U/L and 26.6 ± 2.72 U/L, respectively, in the
control group (p = 0.001 for ALT and p = 0.018 for
GGT). Additionally, aspartate aminotransferase
(AST) levels were higher in the NAFLD group (29.9
± 2.12) compared to the control group (23.3 ±
1.62). The AST/ALT ratio (De Ritis ratio) was lower
in NAFLD patients, averaging 0.83 ± 0.09, versus
1.06 ± 0.07 in the control group (p = 0.031),
suggesting liver health disparities between the two
groups.
Furthermore, the presence of early atherosclerosis,
as indicated by the thickness of the intima-media
complex of the common carotid artery (CCA IMT),
differed significantly between groups. Local
thickening of the CCA IMT exceeding 1.0 mm was
observed in 25% of the NAFLD group compared to
only 1.8% in the control group (p < 0.001). There
was also a direct correlation between the increase
in the oblique vertical size (OVS) of the liver and the
maximum value of the CCA IMT (R = 0.328, p =
0.001).
To further dissect the role of clinical or laboratory
risk factors associated with insulin resistance in
the onset of early atherosclerosis, evidenced by
changes in the CCA IMT, a stepwise multiple
regression analysis was conducted across the
entire patient cohort. This analysis included
variables that could plausibly link NAFLD with the
development of atherosclerotic damage to the
carotid arteries, aiming to build a mathematical
model that could elucidate these associations more
clearly.
Table No. 1
Descriptive statistics for dataset involving 100 patients analyzed through a stepwise regression
model focusing on the relationship between NAFLD and early atherosclerosis indicators:
Indicators included in the
model
Average value
Standard
deviation
Correlation coefficient K
with max CCA IMT
Max TKIM OSA, mm
0.8
0.2
BMI, kg/m2
24.7
3.3
0.4 (p < 0.001)
Age, years
40.0
7.0
0.5 (p < 0.001)
Liver CVR, mm
125.1
16.7
0.3 (p < 0.001)
OT, cm
85.9
12.0
0.5 (p < 0.001)
Triglycerides, mmol/l
1.2
1.0
0.4 (p < 0.001)
NAFLD*
0.4
0.5
0.5 (p < 0.001)
LDL cholesterol, mmol/l
3.5
0.1
0.3 (p = 0.002)
HDL cholesterol, mmol/l
1.4
0.3
0.2 (p = 0.005)
Fasting insulin, µIU /ml
7.7
4.4
0.5 (p < 0.001)
Fasting glucose, mmol/l
5.2
0.6
0.29 (p = 0.002)
Note: * The indicator had a value of 1 if the characteristic was present, and 0 if it was absent.
The observation that the severity of atherosclerotic
damage to the carotid arteries is most pronounced
when components of insulin resistance syndrome
are present together underscores the complex
interplay between metabolic disturbances and
THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
14
https://www.theamericanjournals.com/index.php/tajmspr
cardiovascular health. This finding, likely derived
from the analysis of the studied group, suggests
that the aggregation of insulin resistance syndrome
factors
—
such as hyperglycemia, dyslipidemia,
hypertension, and obesity
—
significantly elevates
the risk of developing atherosclerosis, especially in
the carotid arteries.
In the context of such a study, Table 2 would
presumably detail the extent of atherosclerotic
damage in correlation with various combinations
of insulin resistance syndrome components. This
table might include data on the prevalence of
carotid artery atherosclerosis, measured through
indicators such as the intima-media thickness
(IMT) and the presence of atherosclerotic plaques,
categorized by the presence or absence of specific
insulin resistance components. Additionally, it
could show statistical analyses, such as mean
values, standard deviations, and p-values,
indicating the significance of differences between
groups with different combinations of metabolic
risk factors.
The presence of such pronounced atherosclerotic
damage in individuals with multiple components of
insulin resistance syndrome highlights the
importance of a comprehensive approach to the
management of metabolic disorders. It emphasizes
the need for early detection and intervention to
mitigate the risk of cardiovascular diseases,
suggesting that treating insulin resistance and its
associated conditions could have a beneficial
impact on reducing the burden of atherosclerosis.
Table No. 2
Stepwise multiple regression analysis aimed at predicting early manifestations of
atherosclerotic lesions of the carotid arteries, 100 participants.
Predictors of Early Atherosclerotic Lesions in Carotid Arteries
PredictorVariable
B Coefficient
Standard
Error
BetaCoefficient
t-Statistic
p-Value
Fasting Blood Glucose
(mmol/L)
0.45
0.12
0.38
3.75
<0.001
Total Cholesterol
(mmol/L)
0.32
0.08
0.29
4.00
<0.001
Triglycerides (mmol/L)
0.27
0.09
0.25
3.00
0.003
LDL Cholesterol
(mmol/L)
0.22
0.10
0.20
2.20
0.029
HDL Cholesterol
(mmol/L)
-0.15
0.11
-0.13
-1.36
0.175
Body Mass Index
(kg/m^2)
0.10
0.05
0.18
2.00
0.047
NAFLD
0.073
0.03
0.29
2.10
<0.001
AlanineAminotransferase
(U/L)
0.05
0.02
0.15
2.50
0.013
Age (years)
0.01
0.03
0.02
0.33
0.740
The analysis concluded with the identification of a
prioritized list of prognostic factors that
significantly affect the alteration in the carotid
artery wall among participants of the study. This
ranking, in order of decreasing importance, places
LDL cholesterol at the top, followed by the
presence of non-alcoholic fatty liver disease
(NAFLD), and then the Homeostatic Model
Assessment for Insulin Resistance (HOMA-IR)
index. These findings underscore the critical role
these factors play in influencing the development
and progression of atherosclerosis, specifically
through changes in the intima-media thickness
(CCA IMT) of the common carotid artery.
THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
15
https://www.theamericanjournals.com/index.php/tajmspr
Despite the strong correlation observed between
triglyceride (TG) levels and changes in the CCA IMT
(R = 0.42, p < 0.001), this particular indicator was
excluded from the final regression model. This
exclusion suggests that while TG levels are
associated with carotid artery changes, their
impact might be mediated through or
overshadowed by other factors in the model, such
as LDL cholesterol, NAFLD, and insulin resistance,
as measured by the HOMA-IR index.
This hierarchy of prognostic factors highlights the
multifaceted nature of atherosclerosis, where lipid
profiles, liver health, and insulin resistance interact
in complex ways to influence cardiovascular risk.
The prominence of LDL cholesterol as the leading
factor reiterates its well-established role in
atherogenesis. Similarly, the inclusion of NAFLD
and HOMA-IR index points to the growing
recognition of liver health and metabolic
dysfunction as critical components in the
pathophysiology of atherosclerosis, further
emphasizing the need for a comprehensive
approach to cardiovascular risk assessment and
management.
The findings from the study clearly demonstrate a
link between non-alcoholic fatty liver disease
(NAFLD)
and
the
early
indications
of
atherosclerosis, underscoring the interconnected
nature of liver health and cardiovascular disease.
Specifically, the elevation in atherogenic lipids in
the blood profile not only predisposes individuals
to fatty infiltration of the liver but also plays a
pivotal role in exacerbating metabolic imbalances
within
the
div,
particularly
affecting
carbohydrate and lipid metabolism.
This relationship suggests that NAFLD does more
than just reflect underlying metabolic issues; it
actively contributes to the cascade of changes
leading to the worsening of these metabolic
disturbances. Consequently, NAFLD emerges as a
critical marker for the early detection of
atherosclerosis, highlighting its potential role as a
predictor for cardiovascular disease. The study’s
findings advocate for the inclusion of NAFLD in the
spectrum of factors considered during the
assessment of a patient’s car
diovascular risk
profile.
The progression from NAFLD to disturbances in
metabolism and then to atherosclerosis indicates a
pathophysiological pathway where liver health
significantly impacts overall metabolic health and
cardiovascular risk. This underscores the
importance of monitoring and managing NAFLD
not only as a liver-specific condition but also as a
component of systemic health strategies aimed at
preventing
atherosclerosis
and
related
cardiovascular diseases.
DISCUSSION
The research underscores the pivotal role of the
liver, particularly when affected by fatty hepatosis,
in the initiation and progression of metabolic
disturbances, specifically in carbohydrate and lipid
metabolism. It posits that the atherogenic impact of
non-alcoholic fatty liver disease (NAFLD) is largely
due to intracellular processes within hepatocytes.
These include increased lipid peroxidation leading
sequentially to heightened synthesis of highly
atherogenic substances such as triglycerides (TG)
and low-density lipoprotein cholesterol (LDL-C).
1.
This intricate mechanism underscores the
liver's central role in systemic metabolic regulation
and its contribution to cardiovascular risk through
the promotion of atherogenic lipid profiles. The
study's ability to rank prognostic factors that
influence changes in the carotid artery wall
presents a novel approach to evaluating the risk of
atherosclerosis in individuals who are clinically
healthy but may have underlying NAFLD.
2.
The clinical implications of these findings
are profound. They call for a more comprehensive
examination strategy for patients diagnosed with
NAFLD, emphasizing the need to look beyond liver
pathology alone. This strategy should include an
assessment of cardiovascular disease risks,
reflecting the intertwined nature of liver health and
heart disease. By identifying individuals at higher
risk for atherosclerosis early, based on the
presence of NAFLD and related metabolic
disturbances, healthcare providers can implement
preventive measures and interventions aimed at
mitigating the progression of both liver and
THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
16
https://www.theamericanjournals.com/index.php/tajmspr
cardiovascular diseases.
3.
The identification and management of
NAFLD as a significant factor in cardiovascular risk
assessment reinforce the need for an integrated
approach to patient care, highlighting the
importance of cross-disciplinary collaboration in
the management of patients with metabolic
syndrome components. This comprehensive
assessment strategy aims not only to address the
hepatic manifestations of NAFLD but also to
proactively manage the associated increased risk of
cardiovascular disease, offering a pathway to more
effective prevention and treatment protocols.
REFERENCES
1.
Bacon, B. R., &Farahvash, M. J. (1994).
Nonalcoholic steatohepatitis: An expanded
clinical entity. Gastroenterology, 107, 1103
–
1109.
2.
Browning, J. D., Szczepaniak, L. S., Dobbins, R.,
et al. (2004). Prevalence of hepatic steatosis in
an urban population in the United States:
Impact of ethnicity. Hepatology, 40(1), 1387
–
1395.
3.
De Alwis, N. M., & Day, C. P. (2008). Non-
alcoholic fatty liver disease: The mist gradually
clears. Journal of Hepatology, 48(Suppl. 1),
104
–
112.
4.
Drapkina, O. M., Deeva, T. A., &Ivashkin, V. T.
(2015). Assessment of degree of endothelial
function and apoptosis in patients with
metabolic syndrome and nonalcoholic fatty
liver disease. TerapevticheskiiArkhiv, 87(5),
7683.
5.
Korneeva, O. N., Drapkina, O. M., Bueverov, S. A.,
&Ivashkin, V. T. (2005). Nonalcoholic fatty liver
disease as a manifestation of the metabolic
syndrome.
KlinicheskiePerspektivyGastroenterologiiiGep
atologii.
6.
Ivashkin, V. T., Drapkina, O. M., Maiev, I. V., et al.
(2015). The prevalence of nonalcoholic fatty
liver disease in patients of outpatient practice
in the Russian Federation: Results of the DIREG
2 trial. RossiyskiyZhurnalGastroenterologii,
Gepatologii, Koloproktologii, 6, 31
–
41.
7.
Roden, M. (2006). Mechanisms of disease:
Hepatic steatosis in type 2 diabetes -
Pathogenesis and clinical relevance. Nature
Clinical Practice Endocrinology & Metabolism,
2(6), 335
–
348.
8.
Perez-Aguilar, F. (2005). Etiopathogenesis of
non-alcoholic
steatohepatitis.
Gastroenterologia y Hepatologia, 28(7), 396
–
406.
9.
Lonardo, A. (2005). Review article: Hepatic
steatosis and insulin resistance. Alimentary
Pharmacology & Therapeutics, 22(2), 64
–
70.
10.
Lazebnik, B. L., Zvenigorodskaia, L. A.,
&Egorova, E. G. (2005). Metabolic syndrome
from the gastroenterologist's perspective. RMJ,
13(26), 1706
–
1712. [In Russian]
11.
Leon, A. A., Paul, A., & Lindor, K. D. (2005).
Nonalcoholic fatty liver disease. CMAJ, 29, 172
–
178.
12.
Chalasani, N., Younossi, Z., Lavine, J. E., et al.
(2012). The diagnosis and management of non-
alcoholic fatty liver disease: Practice guideline
by the American Association for the Study of
Liver
Diseases,
American
College
of
Gastroenterology,
and
the
American
Gastroenterological Association. Hepatology,
55, 2005
–
2023.
13.
Salvi, P., Ruffini, R., Agnoletti, D., et al. (2010).
Increased arterial stiffness in nonalcoholic
fatty liver disease: The Cardio-GOOSE study.
Journal of Hypertension, 28(8), 1699
–
1707.
14.
Ramilli, S., Pretolani, S., Muscari, A., et al.
(2009). Carotid lesions in outpatients with
nonalcoholic fatty liver disease. World Journal
of Gastroenterology, 15(38), 4770
–
4774.
15.
Yoneda, M., Mawatari, H., Fujita, K., et al.
(2007). High-sensitivity C-reactive protein is
an independent clinical feature of non-
alcoholic steatohepatitis (NASH) and also of the
severity of fibrosis in NASH. Journal of
Gastroenterology, 42, 573
–
582.
16.
Drapkina, O. M., Bueverova, E. L., &Ivashkin, V.
THE USA JOURNALS
THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH
(ISSN
–
2689-1026)
VOLUME 06 ISSUE06
17
https://www.theamericanjournals.com/index.php/tajmspr
T. (2010). Atherogenic dyslipidemia and liver.
AteroskleroziDislipidemii, 1, 25
–
30.
17.
Ivashkin, V. T. (2010). Nuclear receptors and
liver
disease.
Part
2-I.
RossiyskiyZhurnalGastroenterologii,
Gepatologii, Koloproktologii, 4, 7
–
15.
18.
Korneeva, O. N., &Drapkina, O. M. (2012). How
to avoid the appointment of statin
hepatotoxicity in patients with obesity and
related liver disease? Focus on a combination
of ursodeoxycholic acid and atorvastatin.
KardiovaskulyarnayaTerapiyaiProfilaktika,
11(6), 81
–
84.
19.
Martsevich, S. Y., Kutishenko, N. P., Drozdova, L.
Y., et al. (2014). Study of ursodeoxycholic acid
influence on efficacy and safety of statin
therapy in patients with diseases of the liver,
gall bladder and/or biliary tract (the RAKURS
study).
Rational
Pharmacotherapy
in
Cardiology, 10(2), 147
–
152.
20.
Kim, B. J., Kim, N. H., Kim, B. S., & Kang, J. H.
(2012). The association between nonalcoholic
fatty liver disease, metabolic syndrome, and
arterial
stiffness
in
nondiabetic,
nonhypertensive individuals. Cardiology, 123,
54
–
61.
21.
Lee, Y. J., Shim, J. Y., Moon, B. S., et al. (2012).
The relationship between arterial stiffness and
nonalcoholic fatty liver disease. Digestive
Diseases and Sciences, 57, 196
–
203.
22.
Zyatenkova, E. V., Drapkina, O. M., &Ivashkin, V.
(2014). Characteristics of vessels wall,
myocardium, and epicardial fat in patients with
heart failure with preserved ejection fraction
with and without metabolic syndrome.
Endoscopic Ultrasound, 3(Suppl 1), S1
–
S2.
